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S_mmary We have demonstrated that urinary trypsin inhibitor (UTI) purified from human urine is able to
inhibit lung metastasis of mouse Lewis lung carcinoma (3LL) cells in experimental and spontaneous metastasis
models. In this study, we have investigated whether UTI in combination with an anti-cancer drug, etoposide,
can prevent tumour metastasis and show an enhanced therapeutic effect. Subcutaneous (s.c.) implantation of
3LL cells (I x 106 cells) in the abdominal wall ofC57BL/6 female mice resulted in macroscopic lung metastasis
within 21 days. Microscopic lung metastasis was established by day 14 after tumour cell inoculation, and
surgical treatment alone after this time resulted in no inhibition of lung metastasis. The number of lung
tumour colonies in the group of mice which received surgery at day 21 was greater than in mice which had
tumours left in situ (P = 0.0017). Surgical treatment on day 7, followed by UTI administration (s.c.) for 7
days, led to a decrease in lung metastasis compared with untreated animals. A significant inhibition of the
formation of pulmonary metastasis was obtained with daily s.c. injections of UTI for 7 days immediately after
tumour cell inoculation. UTI administration did not affect the primary tumour size at the time of operation.
In addition, etoposide treatment alone led to smaller primary tumours and yielded reduction of the formation
of lung metastasis in the group of mice which received surgery at day 14 (P= 0.0026). Even in mice which
received surgical treatment on day 14, followed by the combination of UTI (500W g per mouse, days 14, 15, 16,
17. 18. 19 and 20) with etoposide (40mgkg-', days 14, 18 and 22), there was significant reduction of the
formation of lung metastasis (P = 0.0001). Thus, the combination of an anti-metastatic agent with an
anti-cancer drug, etoposide. might provide a therapeutically promising basis for anti-metastatic therapy.
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Tumour cell invasion is required for tumour cell entry into
the vascular system and for extravasation in distant organs.
An increased production of proteolytic enzymes including
urokinase-type plasminogen activator (uPA), plasmin,
cathepsins and collagenases has been associated with the
invasive and metastatic potential of tumour cells (Liotta et
al., 1983; Dano et al., 1985). It has been reported that
protease inhibitors, specific antibodies for these enzymes and
inhibition of the urokinase receptor may prevent cancer cell
invasion (Crowley et al., 1993; Kobayashi et al., 1993).
Urinary trypsin inhibitor (UTI), which is one of the
physiological trypsin inhibitors, was isolated and purified
from human urine. Besides trypsin, UTI exhibits a multipo-
tent inhibitory effect on such proteases as plasmin, human
leucocyte elastase, chymotrypsin, and hyaluronidase (Wach-
ter and Hochstrasser, 1981; Albrecht et al., 1983; Balduyck et
al., 1989; Gebhard et al., 1990). In previous studies, we
demonstrated that UTI inhibited production of experimental
and spontaneous pulmonary metastasis by murine Lewis lung
carcinoma (3LL) cells (Kobayashi et al., 1995a). In addition,
the effective peptide (R-A-F-I-Q-L-W-A-F-D-A-V-K-G-K),
representing the amino acid sequences within the plasmin-
inhibiting domain of the UTI molecule, inhibited both in
vitro tumour cell invasion through basement membrane Mat-
rigel and in vivo 3LL cell lung metastasis in C57BL/6 mice.
Briefly, in an in vivo assay, multiple s.c. injections of UTI
(500;Lg mouse-' day-') for at least 7 days immediately after
s.c. or i.v. tumour cell inoculation significantly inhibited the
formation of lung metastasis in mice. Also, UTI suppressed
the invasion of tumour cells through Matrigel in an in vitro
assay. Fifty per cent inhibition of tumour invasion was
induced by 0.2ylM UTI. UTI inhibited neither cell prolifera-
tion nor the binding of tumour cells to Matrigel, and also
showed no significant suppression of chemotactic migration
of tumour cells to Matrigel and fibronectin (Kobayashi et al.,
1995).
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In the present study we extended our previous study to
examine the inhibitory effect of UTI on lung tumour col-
onies. We focused our attention on the combined effect of
UTI and an anti-tumour agent, etoposide, on lung metas-
tasis. Our studies have concentrated mainly on establishing
preclinical models for the combined effects of UTI and
etoposide.
Materiai and methods
Cells and culture
A murine 3LL cell line, selected for its high lung colonisation
potential, was maintained by serial s.c. transplantation in
C57BL/6 mice. In an in vitro experiment, 3LL cells were
maintained as monolayers in plastic dishes in Eagle's minimal
essential medium supplemented with 10% fetal bovine serum,
sodium pyruvate, non-essential amino acids, L-glutamine and
vitamins (Gibco, Grand Island, NY, USA) at 37C in a
humidified incubator with 5% carbon dioxide in air
(Kobayashi et al., 1994b). The cell viability was determined
by trypan blue dye exclusion before use.
Animals
Specific pathogen-free female C57BL/6 mice, 4-6 weeks old,
were purchased from Charles River Japan, (Kanagawa,
Japan). The care and use of the animals were in accordance
with the Institution's guidelines.
Anti-metastatic or anti-cancer agent
Urinary trypsin inhibitor (UTI): a highly purified preparation
of human UTI with a sp. act. of 2330 U mg-' protein and a
molecular mass of 67 kDa was kindly supplied by Mochida
Pharmaceutical, Tokyo, Japan. The covalent structure of the
polypeptide chain of the physiological inhibitor UTI (HI-30)
has already been determined by Wachter and Hochstrasser
(1981). UTI is used as an anti-metastatic agent.H Kobayasti etat
Etoposide (20 mgml-') was generously provided by Nip-
pon Kayaku, Tokyo, Japan.
Erperimental design
C57BL/6 mice were treated s.c. with UTI with or without
addition of etoposide at various time points after tumour
inoculation. 3LL cells (I x 106 cells 200g1l-' mouse-') were
given as s.c. injections into the abdominal wall. UTI and
etoposide were administered s.c. and i.p. respectively, singly
and in combination for various days after tumour cell
inoculation. The surgical excision of primary tumour was
performed on various days. Surgery was performed under
pentobarbital sodium (5 mg kg-') anaesthesia. All animals
were observed daily. The number of lung tumour colonies
was determined under a dissecting microscope at 28 days
post implantation to verify the presence of tumour in the
lung (Burgers et al., 1989; Saiki et al., 1993a,b).
Experiment I (Figure J) Surgery was performed on days 7
(Figure Id), 14 (Figure lc), or 21 (Figure lb) after initial
3LL cell inoculation. The number oflung tumour colonies of
the animals given s.c. injections of tumour cells and treated
with (Figure lb, c and d) and without operation (Figure la)
was determined.
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Experiment 2 (Figure 2) 3LL cells were given as s.c. injec- tions into the mouse abdominal wall and allowed to grow until palpable. UTI was administered s.c. on various days immediately after tumour cell inoculation and/or after the
surgical excision of primary tumour on day 14. Mice were
randomised into the following five treatment groups (as shown in Figure 2a-e): (a) control I (injection with vehicle; days 0-6 and days 14-20). The surgical excision ofprimary
tumour was not performed; (b) control 2 (injection of vehi-
cle). Surgical excision was performed on day 14 (regimens b,
c, d and e); (c) UTI, 500tLg mouse-' day-', s.c. from days 14
to 20; (d) UTI, 500,.g mouse-' day-', s.c. from days 0 to 6; (e) UTI, 500ytg mouse', from day 0 to day 6 and from day 14 to day 20.
Experiment 3 (Figure 3) The surgical excision of primary tumour was performed on day 7. Each group underwent
treatments using the five schedules as in experiment 2. (a) Control I (injection with vehicle); surgical excision was not
performed; (b) control 2 (injection of vehicle), surgery was
performed on day 7 (regimens b. c, d and e); (c) UTI, 500itg mouse-' day-', s.c. from day 7 to 13; (d) UTI, 500ILg
mouse-' day-'. s.c. from days 0 to 6: (e) UTI, 500 tLg
mouse'. from day 0 to day 13.
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U 7 14 21 28 Figure 1 Effect of surgery at varying 0,0,0,0,0,0,0,0,0,5,28,36,42,50 times on lung metastatic spread of 3LL
cells. Surgery was performed on day 7 (d), 14 (c). and 21 (b) after s.c. tumour cell inoculation. Control serves as mice without operation (a). The data were analysed for significance by the Wilcoxon test. Number of lung tumour colonies (mean ± s.d): (a) 57.75 ± 30.33, (b) 91.86 ± 18.55, (c) 54.60 ± 32.32. (d) 11.50 ± 18.64.
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Figure 2 Effect ofmultiple administra-
tion of UTI combined with operation
at day 14 on the lung metastasis. Surgery was performed on day 14 and multiple injections of UTI according to the various schedules (c. d and e) were carried out. Number of lung tumour colonies (mean ± s.d): (a) 56.64 ± 33.26, (b) 51.50 ± 32.17, (c) 35.79 ± 20.57, (d) 33.79 ± 25.44, (e)
14.43 ± 16.86.
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7 14 21 28 Fgwe 3 Effect of multiple administration of
- 0,0,0,0,0,0,0,0,0,0,0,0,0,0,0 UTI combined with operation at day 7 on the
lung metastasis. Surgery was performed on
day 7 and multiple injections of UTI according to the various schedules (c, d and e) were carried out. Number of lung tumour
colonies (mean ± s.d): (a) 48.33 ± 32.34, (b) 10.00 ± 13.29, (c) 3.92 ± 6.76, (d) 0.87 2.13, (e) 0.00 ± 0.00.
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performed in order to demonstrate the effect
of UTI alone in treatment. Multiple injections of UTI according to the various schedules were carried out. Number of lung tumour
colonies (mean ± s.d.) (a) 44.70 ± 32.25. (b) 26.30 ± 13.70, (c) 46.20 ± 29.20, (d) 47.60 ± 24,22. (e) 25.00 ± 14.20. (f) 30.60 ± 18.28.
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0,0,0,0,0,0,0,0,0,0,0,0,0,1,3 etoposide on lung metastatic spread. Surgery
of the tumour-bearing animals was performed
on day 7 (which can be viewed as a model of the early stage of cancers). (a) PBS (vehicle) alone. (b) UTI 500ILg mouse- day- ' x 7
days immediately after operation, from day 7 to day 13. (c) Etoposide 40 mg kg- on days 7. 11 and 15. (d) UTI and etoposide
combination. Number of lung tumour colonies (mean ± s.d.) (a) 14.43 ± 15.97, (b) 5.00 ± 7.93. (c) 2.69 ± 4.97. (d) 0.27 ± 0.80.
Experirnent 4 (Figure 4) 3LL cells were given s.c. injections
into the mouse abdominal wall and allowed to grow. UTI
was administered s.c. on various days after tumour cell
inoculation. The surgical excision of primary tumour was not
performed in order to demonstrate the effect of UTI alone in
treatment. Sixty animals were randomised into the six groups
of ten mice each, as described in the legend to Figure 4.
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Experinent 5 (Figure 5) Surgery was performed on day 7
after tumour inoculation. Animals were randomised into the
following four treatment groups (as shown in Figure 5): (a)
control, vehicle only; (b) UTI, 500 Ig mouse-' day-', S.C.
injection, from day 7 to day 13; (c) etoposide 40mg kg-',
treatments were administered by i.p. injection every 4th day
for 8 days with a total of three doses (on days 7, 11 and 15);
(d) combination, UTI + etoposide.
Experiuent 6 (Figure 6) Surgical excision was performed
on day 14 post tumour inoculation. Animals were ran-
domised into the following four treatment groups (as shown
in Figure 6): (a) control, vehicle only;, (b) UTI, 500 Ig
mouse'l day-', s.c. injection, from day 14 to day 20; (c)
etoposide 40mg kg-', treatments were administered by i.p.
injection every fourth day for 8 days with a total of three
doses (on days 14, 18 and 22); (d) combination, UTI-
+ etoposide.
Experinent 7 (Figure 7) The effect of etoposide alone in
treatment was demonstrated. Tumour nodules were allowed
to grow and each group (n = 9) underwent etoposide treat-
ment usig the same treatment schedules and doses as used
for experiments 5 and 6. The surgical excision of primary
tumour was not performed.
Statistical analysis
The data were analysed for sign by the Wilcoxon test.
Res
Effect ofsurgical excision oftwnour at various times on lung
metastatic spread of3LL cells
Surgery was performed on days 7, 14 or 21 after s.c. tumour
cell inoculation (Figure 1). Two mice (experiment 1, regimen
b) were lost from the study. These animals died within 24 h
of surgery from surgically related haemorrhage. Otherwise,
there was no surgical failure at the site of surgical resection.
Controls were not operated upon (Figure la). The effect of
various times of surgery was evaluated with respect to the
number of lung tumour colonies. Note that the number of
lung tumour colonies in mice receiving surgery on day 21 was
significantly increased compared with those mice without
operation (P= 0.0017; Figure la). Microscopic lung metas-
tasis was established by day 14 after s.c. tumour cell inocula-
tion (data not shown) and surgical treatment alone on or
after day 14 might result in no cures (Figure lb and c). Also,
surgery performed on day 14 did not reduce the number of
lung tumour colonies (P = 0.7965; Figure lc). On the other
hand, surgery performed on day 7 siifintly reduced the
number of lung tumour colonies (P= 0.0001; Figure Id).
In addition, sham surgery was performed as a control for
the surgery because anaetheia and surgical stress can alter
tumour metastasis. With respect to the number of lung
tumour colonies, no significant differences were found in
sham surgery as compared with untreated controls (data not
shown).
Effect ofmultipke administration of UTI combined with
operation at varying times on the hlng metastasis
We examined the effects of surgery and UTI administration
on lung metastasis of 3LL cells usig a spontaneous metas-
tasi assay. Surgery was performed on day 14 and multiple
injections of UTI according to the various schedules were
carried out (Figure 2). Most animals had evidenc ofmicros-
copic lung metastatic spread when surgey was performed on
day 14 (Figure 2b). Significnt inhibition of3LL spontaneous
lung metastasis was obtained with sequential s.c. administra-
tion of UTI for 7 days immediately after tumour inoculation
(Figure 2e vs a, b, c and d). The schedule e showed a
sigificantly reduced lung metastasis as compared with
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cIschedules a (P = 0.0006), b (P = 0.0010), c (P = 0.0083) and
d (P = 0.0420). Multiple injections of UTI for 7 days, from
day 14 to day 20, immediately after surgery did not
significantly decrease the number of lung tumour colonies
(P= 0.2320) (c vs b).
In addition, surgery was performed on day 7 and multiple
injections of UTI according to the various schedules were
carried out (Figure 3). We investigated the effects of com-
binations of operation on day 7 with UTI to evaluate wheth-
er they could improve the number of lung tumour colonies.
In the group of mice which reived surgery at day 7 (Figure
3b, c, d and e), no significnt inhibition of 3LL spontaneous
lung tastasis was obtained with schedules c and d includ-
ing sequential s.c. administration of UTI. The administration
of UTI for 7 days, from day 7 to day 13, imediately after
surgery did not decrease the number of lung tumour colonies
(P = 0.3264) (b vs c). However, the adminisation of UTI
for 14 days, from day 0 to day 13, immiately after tumour
cell inoculation decreased the number of hmg tumour col-
onies (P = 0.0077). In the animals with regimen e, surgery on
day 7 enhanced the anti-metastatic activity of UTI. Even in
the animals which received sequential s.c. administration of
UTI for 7 days immiately after tumour inoculation, addi-
tional injections of UTI for 7 days imeitely after surgery
did not result in the reduction of the number of hmg tumour
colonies (P=0.0797) (e vs d).
We demonstrated the effect of UTI alone in treatment.
UTI was inistered s.c. on various days after tumour cell
inoculation (Figure 4). UTI treatment aely after
tumour inoculation (Figure 4, reens b, e and f) led to a
slight decrease in metastasis. Tnhibition of the formation of
spontaneous lung metastasis is documented for UTI when
injected daily within the first 7-14 days after s.c. injection of
the tumour cells. No effect on the growth of primary tumour
was d d. We confirmed that UTI has no
cytotoxic-cytostatic effect. We can be sure that these effects
are anti-metastatic, although we would probably get the same
results from a cytotoxic-cytostatic agent, particularly as the
best results come from a 14 day continuous schedule (Figure
4e).
Combined effect of UTI and an anti-cancer agent on ting
metastatic spread
Surgery of tumour-bearing animals was performed on day 7
(which can be viewed as early stage of cancels), since lung
meastasis was well established by day 14 (Figure 2; regmen
c). Fifty-five animals were randomised into four groups and
we examined the effect of combination therapy on lung
metastass (Figure 5). The combination treatment (Figure 5d)
reduced the number of lung tumour colonies significantly
compared with the untreated control (P=0.0059; Figure 5a),
suggesting that the combination group (Figure 5d) will show
signifiantly prolonged survival periods. No benefit was
noted with UTI single therapy compared with untreated
controls (P= 0.1097; Figure 5b vs a). Etoposide alone did
not lead to a reduced metastatic spread (P = 0.0890; Figure
5c vs a).
In addition, based on the demonstration that 14 days of
tumour growth produced microscopic lung mtastasis even in
those mice that received surgery, we tested the effects of UTI
and chemotherapy in this system (Figure 6; which can be
viewed as advanced stage of cancers). Mice were randomised
into four groups as described above. Etoposide when used as
a single agent demonstrated some tumour growth inhibition,
since three mice had no evidence of metastatic lung colonies.
The combination treatment (Figure 6d) reduced the number
of lung tumour colonie significntly compared with the
administration of UTI (P=0.0008; Figure 6b) or etoposide
alone (P=0.0073; Figure 6c), or the untreated controls
(P 0.0001; Figure 6a).
The effect of etoposide alone in treatment has been demon-
strated (Figure 7). All tumours in the etoposide group con-
tinued to grow after discontinuation of chemotherapy.
Etoposide treatment led to a smaler primary tumour growth
H Kobeyastu et a
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and showed reduction ofthe number oflung tumour colonies
compared with untreated controls.
There are several reports that cell surface proteolytic enzymes
are essential to the metastatic process of tumour cells (Liotta
et al., 1983; Dano et al., 1985; Mignatti et al., 1986; Reich et
al., 1988; Cajot et al., 1989). Treatments with antibodies or
specific inhibitors of uPA or plasmin have shown promise in
inhibiting tumour cell invasion and metastasis (Ossowski and
Reich. 1980, 1983; Ostrowski et al., 1986; Hearing et al.,
1988; Ossowski, 1988). In addition, competitive displacement
of uPA from celular uPA receptor (uPAR) decreases
plasminogen-dependent degradation of extracellular matrix
and basement membrane proteins by tumour cells, suggesting
the prevention of metastasis by inhibition of the uPAR
(Crowley et al., 1993). The number of lung tumour colonies
following s.c. injection of tumour cells was decreased by
preincubation of the tumour cells with anti-uPA antibody
(Kobayashi et al., 1994b). However, the difficulties in clinical
use of antibodies have been considered because antibodies
induce severe complications which limit prolonged administ-
ration
In addition, occupation of uPA receptors on human
ovarian cancer HOC-I cells or mouse Lewis lung carcinoma
3LL cells by enzymatically inactive human amino-terminal
fragment (ATF; receptor-binding domain of uPA) or mouse
peptide 17-34 speifically reduced tumour cell invasion, sug-
gesting that prevention of rebinding of uPA synthesised by
tumour cells to the receptor inhibits tumour cell metastasis
(Kobayashi et al., 1995).
The possibility of UTI acting as an anti-metastatic agent
has been reported (Kobayashi et al., 1994a, d). According to
our previous reports, UTI's enhancement of anti-metastatic
activity may result from its inhibitory effects on cell-
associated plasmin activity (Kobayashi et al., 1994d), and
that UTI efficiently regulates the mechanism involved not
only in the entry into vascular circulation of tumour cells
(intravasation) through, at least in part, inhibition of the
proteolytic enzyme, plasmin, but also in the extravasation
step, during the metastatic process (Kobayashi et al., 1994d,
1995). Since UTI has no anti-tumour activity, however, UTI
treatment alone resulted in excessive growth of primary
tumour and no cures. To provide a therapeutically promising
basis for the prevention of cancer metastasis, we examined
the effects of UTI in combination with etoposide on anti-
tumor activity (Burgers et al., 1989; Saiki et al., 1993a, b). To
extend our previous observations on the inhibition of the
formation of lung tumour colonies by UTI, we examined
whether the combination of UTI with etoposide can lead to
encement of its inhibitory effect on tumour metastasis.
This study on the therapeutic effects of combining UTI
with etoposide on the Lewis lung tumour could appear to
demonstrate clinical potential. Anti-metastatic therapy as
proposed in this study is an inresting concept that is
crifically time dependent. Some of the observed pulmonary
metastasis probably occur dunng the initial subcutaneous
3LL cell injections to form the primary tumours. This poten-
tial source ofpulmonary metastasis, as opposed to metastasis
arising from the primary tumour itself, is also important in
forming hmg tumour colonisation. The effect of UTI by itself
is most prominent when administereA at the sae time as or
shortly after tumour inoculation and continued until the
primary tumour is removed. If one waits for 14 days after
inoculation to give the UTI little effect is seen, presumably
because the hmgs are already seeded. Therefore, the window
of opportunity to effect tastasis is limited primarily to
when few or no cells have seeded the lungs. In this case
surgery is relatively effective by itself. With this concept in
mind we discuss the potential clinical application of our
protocols.
In the 3LL model, surgery alone on day 7 may improve
the survival time by removing tumours before many cells hadop H Kobayasl eti
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extravasated. In the early stage of cancer, the administration
of UTI in combination with surgery on day 7 did not inhibit
lung metastasis. In the group of animals which received
surgical excision of the primary tumours on day 14 however,
multiple administrations of UTI (days 0-6 and days 14-20)
significantly inhibited spontaneous lung metastasis. Note that
the number oflung tumour colonies ofmice receiving surgery
on day 21 was significantly increased compared with those
without operation, suggesting that resection of large primary
tumours may increase more shedding at surgery (Burgers et
al., 1989).
The anti-tumour activity observed in mice treated with
etoposide only was significantly enhanced by combination
with UTI in the multiple administration schedule. Combining
UTI and etoposide increased anti-tumour activity, when
surgery was performed on day 7 (which can be viewed as a
model for the early stage ofcancers) or on day 14 (which can
be viewed as a model for the advanced stage ofcancers) after
tumour cell inoculation.
The design of combined treatments, including timing,
doses and schedules, will need to be improved and optimised
to further enhance the anti-metastatic effect. In clinical trials
in the future, UTI can be used as adjuvant therapy at the
same time as or shortly after cytoreduction or, more interest-
ingly, as part of combination treatment with antineoplastic
drugs. Since UTI seems to be a biological response modifier,
it is more likely to be effective when used in combination
with other anti-tumour agents.
The exact mechanism of action of UTI is still unclear, but
it is thought that UTI inhibits cell-associated plasmin
activity. In addition, our previous studies provide novel in-
formation on the plasma membrane UTI-specific binding
sites on some tumour cells including 3LL cells (Kobayashi et
al., 1994J). UTI is not an integral membrane glycoprotein but
is bound to a specific surface receptor that is incompletely
saturated. Bound UTI retains its protease inhibiting activity
(plasmin and trypsin inhibiting activities; our unpublished
data).
We suggest a model for the proposed interaction of UTI
and receptors on the surface of invading tumour cells as
follows: Plasmin(ogen) attaches to plasmin(ogen) receptor on
the cell surface and it allows the tumour cells to invade
extracellular matrix. UTI, exogenously added to the cells,
attached to its receptor on the tumour cell surface efficiently
inhibits plasmin activity in the close environment of the cells
and thus it contributes to prevent tumour cell invasion and
metastasis. UTI may play a regulatory role in uPA/plasmin-
dependent tumour cell invasion and metastasis. Thus, UTI
might provide a therapeutically promising basis for the
prevention of tumour metastasis as an anti-metastatic agent.
In general, the clinical application ofan agent such as UTI
may be fraught with difficulty. It is likely that prolonged
administration would be necessary with all the ensuing conse-
quences. The experimental schedules used in this study would
not reveal these potential problems. However, the molecule is
unlikely to be antigenic, since UTI is therapeutically promis-
ing for the treatment of acute pancreatitis in Japan.
With respect to the effect of UTI, our in vivo observations
in animal models may guide future clinical trials. However,
further investigations need to be performed to confirm these
preliminary in vivo results in other tumour models and to
evaluate the clinical side-effects from chemotherapy in com-
bination with UTI for the treatment of human cancer.
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